Диссертация (1154755), страница 15
Текст из файла (страница 15)
2015; 115: 1-7.61.King DS, Wilburn AJ, Wofford MR, et al. Cognitiveimpairment associated with atorvastatin and simvastatin. Pharmacotherapy2003; 23(12): 1663–7.62.Koh KK, Sakuma I, Quon MJ. Differential metabolic effects ofdistinct statins. Atherosclerosis. 2011; 215(1): 1-8.63.Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: AEuropean Society of Cardiology survey on the lifestyle, risk factor andtherapeutic management of coronary patients from 24 European countries. Eur J105PrevCardiol.2015Feb16.doi:10.1177/2047487315569401.pii:2047487315569401. [Epub ahead of print].64.Krishnaswamy G, Kellet J, Year L, et al. Human endotheliumas a source of multifunctional cytokines: molecular regulation and possible rolein human disease. J Interferon Cytokine Res.
1999; 19: 91–104.65.Kruit JK, Kremer PHC, Dai L et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDLreceptor influences cholesterol-induced impairment of beta cell function inmice. Diabetologia 2010; 53: 1110-1119.66.Larsson PT, Hallerstam S, Rosfors S, et al.
Circulating markersof inflammation are related to carotid artery atherosclerosis. Int Angiol. 2005;24(1): 43-51.67.Lee SJ, Bell DA, Coulter SJ, et al. Recombinant CYP3A4*17 isdefective in metabolizing the hypertensive drug nifedipine, and theCYP3A4*17 allele may occur on the same chromosome as CYP3A5*3,representing a new putative defective CYP3A haplotype.
J Pharmacol ExpTher. 2005; 313(1): 302-309.68.dementiaLi G, Higdon R, Kukull WA, et al. Statin therapy and risk ofintheelderly:acommunity-basedprospectivecohortstudy. Neurology. 2004; 63: 1624–1628.69.Li L, Sun T, Zhang P, et al. Statins for primary prevention ofvenous thromboembolism. Cochrane Database Syst Rev. 2011; 12: CD008203.70.Li Q, Deng SB, Xia S, et al. Impact of intensive statin use onthe level of inflammation and platelet activation in stable angina afterpercutaneouscoronaryintervention:aclinicalstudy. MedClin(Barc).
2013; 140: 532–536.71.Li Y, Liu Y, Fu L, et al. Efficacy of short-term high-dose statinin preventing contrast-induced nephropathy: a meta-analysis of sevenrandomized controlled trials. PLoS One 2012; 7:e34450.10672.Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care SpecPharm. 2016; 22: 685–698.73.Luijendijk HJ, Stricker BH, Hofman A, et al. Cerebrovascularrisk factors and incident depression in community-dwelling elderly. ActaPsychiatr Scand.
2008; 118: 139–148.74.Macedo AF, Taylor FC, Casas JP, et al. Unintended effects ofstatins from observational studies in the general population: systematic reviewand meta-analysis. BMC Med. 2014; 12: 51.75.Machan CM, Hrynchak PK, Irving EL. Age-related cataract isassociated with type 2 diabetes and statin use.
Optom Vis Sci. 2012; 89(8):1165-1171.76.Maki KC, Ridker PM, Brown WV, et al. An assessment by theStatin Diabetes Safety Task Force: 2014 update, J Clin Lipidology, 2014; 8(3Suppl): S17–S29.77.Maningat P, Gordon BR, Breslow JL. How do we improvepatient compliance and adherence to long-term statin therapy? Curr AtherosclerRep.
2013; 15(1): 291.78.Martin SS, Blumenthal RS, Miller M. LDL cholesterol: thelower the better. Med Clin North Am. 2012; 96: 13-26.79.loweringMcCarty CA, Mukesh BN, Guymer RH, et al, Cholesterolmedicationsreducetheriskofage-relatedmaculopathyprogression. Med J Aust. 2001;175:340.80.McGuinness B, Craig D, Bullock R, et al. Statins for thetreatment of dementia. Cochrane Database Syst Rev. 2014; 7: CD007514.81.McGwin G Jr, Modjarrad K, Hall TA, et al. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-relatedmaculardegenerationinOphthalmol.
2006; 124: 33–37.theCardiovascularHealthStudy.Arch10782.Michelis KC, Hassouna B, Owlia M, et al. Effect of ElectronicPrescription on Attainment of Cholesterol Goals. Clin Cardiol. 2011 Apr; 34(4):254-60.83.Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairsexercise training adaptation. J Am Coll Cardiol 2013; 62: 709–714.84.Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statintreatment for cardiovascular disease: a network meta-analysis of 170,255patients from 76 randomized trials.
QJM. 2011;104(2): 109-124.85.Mohassel P, Mammen AL. The spectrum of statin myopathy.Curr Opin Rheumatol. 2013; 25(6): 747-52.86.Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associateswith a lower incidence of acute kidney injury after major elective surgery. J AmSoc Nephrol. 2011; 22: 939–946.87.Muldoon MF, Rossouw JE, Manuck SB, et al. Low or loweredcholesterol and risk of death from suicide and trauma. Metabolism 1993; 42:45–56.88.Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on theadipocyte maturation and expression of glucose transporter 4 (SLC2A4):implications in glycaemic control. Diabetologia. 2006; 49: 1881-1892.89.Nielsen SF, Nordestgaard BG. Negative statin-related newsstories decrease statin persistence and increase myocardial infarction andcardiovascular mortality: a nationwide prospective cohort study. Eur Heart J.2016; 37: 908–16.90.Bays H, Cohen DE, Chalasani N, et al.
An assessment by theStatin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014; 8(3 Suppl):S47-57.91.OʼBrien SE, Schrodi SJ, Ye Z, et al. Differential LipidResponse to Statins Is Associated With Variants in the BUD13-APOA5 GeneRegion. J Cardiovasc Pharmacol. 2015; 66(2): 183-188.10892.Okifuji A, Hare BD. The association between chronic pain andobesity. J Pain Res 2015 Jul 14; 8: 399-408.93.Olsson AG, Lindahl C, Holme I, et al. Incremental Decrease inEnd Points Through Aggressive Lipid Lowering Study Group. LDL cholesterolgoals and cardiovascular risk during statin treatment: the IDEAL study. Eur JCardiovasc Prev Rehabil.
2011; 18: 262–269.94.O'Neil A, Sanna L, Redlich C, et al. The impact of statins onpsychological wellbeing: a systematic review and meta-analysis. BMC Med2012; 10: 154.95.Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associatedmemory loss.
Pharmacotherapy 2001; 21(6): 767–9.96.Ott BR, Daiello LA, Dahabreh IJ, et al. Do Statins ImpairCognition? A Systematic Review and Meta-Analysis of Randomized ControlledTrials. J Gen Intern Med 2015 Mar; 30(3): 348-58.97.Parker BA, Polk DM, Rabdiya V, et al. Changes in memoryfunction and neuronal activation associated with atorvastatin therapy.Pharmacotherapy 2010; 30(6):236e–40e.98.Pedersen TR, Faergeman O, Kastelein JJ, et al. IncrementalDecrease in End Points Through Aggressive Lipid Lowering (IDEAL) StudyGroup High-dose atorvastatin vs usual-dose simvastatin for secondaryprevention after myocardial infarction: the IDEAL study: a randomizedcontrolled trial.
JAMA. 294 2005: 2437-2445. Erratum in: JAMA 2005; 294:3092.99.Permission for questionnaire SF-36 use. OPTUMINSIGHTNON-COMMERCIAL LICENSE. Lic.№: SLA QM0380024-CT183072OP057524. https://campaign.optum.com/content/optum/en.html100.Petersen RC. Mild cognitive impairment. N Engl J Med. 2011;364: 2227–2234.101.Poduri A, Khullar M, Bahl A, et al. Common Variants ofHMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 Genes as Predictors109of Lipid-Lowering Response to Atorvastatin Therapy. DNA AND CELLBIOLOGY. 2010; 29 (10): 629–637.102.Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogeneticmeta-analysis of genome- wide association studies of LDL cholesterol responseto statins. Nat Commun.
2014; 5: 5068.103.Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabeteswith intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA. 2011; 305(24): 2556-64.104.Prowle JR, Calzavacca P, Licari E, et al. Pilot double-blind,randomized controlled trial of short-term atorvastatin for prevention of acutekidney injury after cardiac surgery. Nephrology (Carlton).
2012; 17: 215–224.105.PulkkinenA, ViitanenL, Kareinen A, etal. MspIpolymorphism at + 83 bp in intron 1 of the human apolipoprotein A1 gene isassociated with elevated levels of HDL cholesterol and apolipoprotein A1 innondiabetic subjects but not in type 2 diabetic subjects with coronary heartdisease.
Diabetes Care. 2000; 23 (6): 791–795.106.Putzer G, Roetzheim R, Ramirez AM, et al. Compliance withrecommendations for lipid management among patients with type 2 diabetes inan academic family practice. J Am Board Fam Pract. 2004 Mar-Apr; 17(2):101-7.107.loadingQuintavalle C, Fiore D, De Micco FD, et al. Impact of a highdoseofatorvastatinoncontrast-inducedacutekidneyinjury. Circulation. 2012;126: 3008-3016.108.Rahimi K, Emberson J, McGale P, et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
